With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, Guardant Health is taking its Shield blood test on the road in hopes of tackling ...

Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...

In an effort to boost global biopharma competitiveness, the U.K.’s National Institute for Health and Care Research (NIHR) has ...

The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate. | Bayer has discontinued an early-stage clinical gene therapy for a rare ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet ...

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

Medimaps markets AI-driven bone microarchitecture imaging technologies such as TBS Osteo and TBS Reveal, which assess ...